cyrilzakka/clinical-trials huggingface dataset:
Metabolic Biomarkers in Thoracic Cancers

The purpose of this research study is to develop a method of using magnetic resonance imaging (MRI) to evaluate lung tumors and other thoracic malignancies. An MRI is a scanning device that uses magnets to make images (pictures) of the body. This study is being done to determine what series of reactions (metabolic pathways) pulmonary nodules use as they burn sugar as fuel for growth. The manner in which the tumor burns (metabolizes) sugar for fuel is being investigated by using a natural, slightly modified, sugar solution (13C-glucose) and studying a small sample of the tumor once it is removed at the time of surgery.

The recent report of the findings of the National Lung Screening Trial indicates that screening a high-risk population using low dose CT results in a 20% reduction in lung cancer mortality. At our institution, some of positive nodules that are 1 cm or larger would be imaged using combined fluoro-deoxyglucose positron emission tomography (FDG PET)/CT. Highly suspicious nodules would be biopsied if the risks were manageable. Otherwise, the suspicious nodules not eligible for biopsy and so-called "indeterminate" nodules are followed using CT to be evaluated for interval growth.

The overall goal of this project is to assess several very promising imaging biomarkers that can reflect either the physiological or metabolic status of these nodules in order to develop more accurate imaging algorithms for follow-up that are either less invasive or do not use ionizing radiation or both. Based on our experience with other cancers and our preliminary results in lung cancer, we have identified four potential imaging studies that we believe have the potential to result in validated "imaging biomarkers" that can either individually, or in combination, characterize malignancies. Since tumors tend to exhibit angiogenesis and altered vascular permeability, we and others, have found that analyses of dynamic contrast enhanced MRI (DCEMRI) can be employed as "imaging biomarkers" for malignancy. Tumors often exhibit higher cellularity than benign or normal tissue suggesting that pixel-by-pixel ADC values derived from diffusion weighted MRI could be useful imaging biomarkers. Finally, measuring alterations in metabolic fluxes through the use of pathway specific C-13 labeled compounds, a technique pioneered here at the Advanced Imaging Research Center (AIRC) at UT Southwestern, has shown the capability of providing metabolic fingerprints for malignant and benign tissue. This approach, while invasive, could identify and validate markers that can be detected non-invasively in future studies. We will also employ advanced metabolomics methods to identify potential signature "onco-metabolites" in these lung cancers.

Eligibility Criteria:
Inclusion Criteria:

1. Patients must have known or probable malignant lesions requiring surgical biopsy or excision.
2. Subjects of all races and ethnic origins over 18 years of age.

Exclusion Criteria:

1. Not a surgical candidate.
2. Poorly controlled diabetes.
the Real-world Data of Risk Factor and Its Prognosis in PREmature Coronary ARtery DIseAse Study

The goal of this observational study is to explore the relationship between biological aging and long-term prognosis of patients with metabolic cardiovascular disease in premature coronary artery disease. The main question\[s\] it aims to answer \[is/are\]:

1. Do patients with premature coronary heart disease have accelerated biological aging?
2. What is the prognosis of accelerated biological aging in patients with premature coronary heart disease?


Eligibility Criteria:
Inclusion Criteria:

* Male or female inpatients over 18 years old in the Department of Cardiovascular Medicine;
* Patients with one of the following metabolic cardiovascular diseases \[17\]: including diabetes, hypertension, coronary heart disease, heart failure, cerebral infarction, dyslipidemia, obesity and hyperuricemia;
* Those who have corresponding inspection data so as to be able to calculate the biological age;
* Obtaining oral informed consent or signing an informed consent form;

Exclusion Criteria:

·NA
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).

This is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded study of Hydroxychloroquine (HCQ) post-exposure prophylaxis (PEP) for the prevention of SARS-CoV-2 infection in adults exposed to the virus.The overarching goal of this study is to assess the effectiveness of HCQ PEP on the incidence of SARS-CoV-2 detection by polymerase chain reaction (PCR) to inform public health control strategies.This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) at baseline who are close contacts of persons with PCR-confirmed SARS-CoV-2 or clinically suspected COVID-19 and a pending SARS-CoV-2 PCR test. Eligible participants will be enrolled and randomized 1:1 to HCQ or ascorbic acid at the level of the household (all eligible participants in one household will receive the same intervention). Participants will be counseled about the preliminary in vitro data on HCQ activity against SARS CoV-2 and equipoise regarding efficacy in humans.The duration of study participation will be approximately 28 days.

Eligibility Criteria:
Inclusion Criteria:

* Men or women 18 to 80 years of age inclusive, at the time of signing the informed consent
* Willing and able to provide informed consent
* Had a close contact of a person (index) with known PCR-confirmed SARS-CoV-2 infection or who is currently being assessed for COVID-19. Close contact defined as:

  1. Household contact (i.e., residing with the index case in the 14 days prior to index diagnosis)
  2. Medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)
* Less than 4 days since last exposure (close contact with a person with SARS-CoV-2 infection) to the index case
* Body weight \< 100 kg (self-reported)
* Access to device and internet for Telehealth visits

Exclusion Criteria:

* Known hypersensitivity to HCQ or other 4-aminoquinoline compounds
* Currently hospitalized
* Symptomatic with subjective fever, cough, or sore throat
* Current medications exclude concomitant use of HCQ
* Concomitant use of other anti-malarial treatment or chemoprophylaxis
* History of retinopathy of any etiology
* Psoriasis
* Porphyria
* Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes \< 1500) or thrombocytopenia (\< 100 K)
* Concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen
* Known liver disease
* Known long QT syndrome
* Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs, or planned use during the study period
Improving the STOP-Bang Screening Questionnaire for Patients With Sleep Apnea

The study is being conducted to test the ability of a simple questionnaire to detect mild, moderate or severe obstructive sleep apnea. The investigators are also investigating whether adding the size of the neck and waist can add to the accuracy of the questionnaire.

The study will be conducted at the Center for Sleep Medicine at Tufts Medical Center. The investigators hope to enroll 250 patients in our study at Tufts Medical Center.

We will complete a 12 item questionnaire and data sheet with the study subjects based on their responses and 2 measurements specified below, right before application of a study the start of their sleep study called "Polysomnography".

If available, we will also use information from the subjects medical record, including information regarding a history of diabetes (blood sugar that is too high), high blood pressure and laboratory data such as blood sugar and blood lipids (fats in the blood). We will record this information for research purposes.

The 2 measurements performed for research purposes consist of the size of the neck and waist using a flexible tape measure. After the sleep study, we will also use results from that study in this research. We expect the subjects study participation to be completed in 30 minutes or less.

There will be no follow up. If a participant cannot complete the sleep study for any reason, the study team may decide to withdraw the subject's participation without further notice.

The study will be open for participation from June 2012 through November of 2012.

Eligibility Criteria:
Inclusion Criteria:

* Referral to the sleep center for a diagnostic study
Preterm Infants: Light Effects on Health and Development

Preterm babies cared for in the intensive care nursery are exposed to amounts of light that are very different from the exposures to an unborn baby or the newborn term baby. Currently many nurseries try to protect premature babies from too much light. They may also try to create light conditions of day and night like many parent homes. Some studies have shown improvements in health and development of babies cared for in nurseries that try to change light for premature babies.


Eligibility Criteria:
Inclusion Criteria:

* Infants were \< 7 days of age and were born at 28 weeks or \< 28 weeks

Exclusion Criteria:

* known anomalies associated with neurological or visual problems (e.g., congenital glaucoma, Down Syndrome)
A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes

This study is comparing the effect of a long-acting insulin analogue (insulin 287) with insulin glargine (Lantus®) in subjects with type 2 diabetes. In addition, the study is looking at symptoms of low blood sugar, awareness of low blood sugar and the time and amount of glucose needed to recover from low blood sugar after injecting 2 and 3 times the basal dose of insulin 287 and glargine. The purpose of the study is to make a once-weekly injectable basal insulin treatment for people with type 2 diabetes. Participants will get insulin 287 as well as insulin glargine - which treatment any participant gets first is decided by chance. Insulin 287 is a new medicine; insulin glargine can already be prescribed. The study medicines will be in a pen, and must be injected with a needle in the thigh once per day (insulin glargine) or once per week (insulin 287). The study will last for minimum 3 months and up to approximately 6 months. Participants will have 21 clinic visits and at least 2 phone calls with the study doctor. The participants' health will be monitored carefully and blood samples will be taken at the clinic visits.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged between 18 and 72 years (both inclusive) at the time of signing informed consent.
* Body mass index between 18.5 and 37.9 kg/m\^2 (both inclusive).
* Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening.
* Glycosylated haemoglobin type A1c (HbA1c) less than or equal to 9.0% (less than or equal to 74 mmol/mol) at screening.
* Current total daily insulin treatment between 0.2 and 1.0 U/kg/day (both inclusive).

Exclusion Criteria:

* Known or suspected hypersensitivity to trial products or related products.
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method.
* Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus).
Acupuncture-like Transcutaneous Electrical Nerve Stimulation on Bowel Symptom and Quality of Life in Patients With Irritable Bowel Syndrome

To discuss the effects of improving the irritable bowel syndrome patients' quality of life and defecation after implementing acupuncture-like Transcutaneous Electrical nerve stimulation.

This experiment will use a clinical design that will collect cases in a local teaching hospital. The way of convenience sampling will gather from the irritable bowel syndrome patients. After a questionnaire, randomly to make invention and control groups. Invention and control groups are 4 weeks and 3 weeks respectively. Each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment. The Control group will still have normal nursing. There will be 72 patients in two groups. The measured timing will be in the second, fourth, and eighth weeks after the prediction and invention.

Eligibility Criteria:
Inclusion Criteria:

1. Those who are at least 20 years old (inclusive) and are willing to sign a written informed consent after explaining the purpose of the research.
2. A patient with irritable bowel syndrome diagnosed by a doctor for at least 6 months (inclusive).
3. Communicate in Mandarin or Hokkien.

Exclusion Criteria:

1. Those who cannot take care of themselves in daily life.
2. Those who have had severe abdominal and colorectal surgery.
3. Those who have been diagnosed with inflammatory bowel disease or colorectal cancer.
4. Those with a history of mental illness, such as schizophrenia and obsessive- compulsive disorder.
5. Women who are pregnant, breastfeeding, and less than 12 months after delivery.
6. Other serious diseases, such as acute myocardial infarction, endocrine disease, decompensated cirrhosis, stroke, and end-stage renal disease, etc.
Brain Exercises for Synaptic Plasticity

The BEST study will investigate the feasibility of cognitive interventions in a randomized, placebo-controlled, clinical trial. The investigators will recruit 45 cognitively normal subjects and engage them in one of three cohorts over an 8 week period, including active reading vs. origami study arms and a placebo group without structured cognitive intervention.

This is a randomized, placebo controlled study investigating the practical implementation and conduct of two cognitive interventions in non-demented subjects. Subjects will be randomized 1:1:1 into three groups including: 1) a Book club that includes weekly one hour meetings and daily reading assignments, 2) Origami lessons (one hour/week) with daily take home Origami activities to complete, and 3) a placebo group with unstructured lifestyle activities (normal lifestyle activities without restraint).

Eligibility Criteria:
Inclusion Criteria:

* Non demented community dwelling elders

Exclusion Criteria:

* Unable to perform the reading or origami tasks for any reason
Pupillometry-guided Remifentanil Infusion Versus Conventional Administration in Children

Our study aims to compare the total intravenous dose of remifentanil per anesthesia hour and body weight in two groups of pediatric surgical patients - an interventional group with remifentanil infusion under pupillometry monitoring, and control group without pupillometry - to figure out whether pupillometry monitoring may reduce remifentanil consumption during anesthesia while providing sufficient analgesia for surgical noxious stimuli.

comparison of total used opioid

Eligibility Criteria:
Inclusion Criteria:

* Pediatric patients who are at 3 to 6 years of age, scheduled to undergo elective surgery with estimated time of operation 2 hours or longer, under general anesthesia
* American Society of Anesthesiologists physical status classification (ASA class) I - II
* Patient and his/her parents are willing to participate after explanation of the purpose, materials, methods, possible risks and benefits of the research

Exclusion Criteria:

* History of hypersensitivity/allergic reaction to the drugs which are used in general anesthesia
* Preoperative use of analgesics, antipsychotics and/or antiepileptics
* Mental retardation
* Medications related to hindrance of autonomic nerve system activity, e. g., beta blockers
* Underlying ophthalmic diseases
Damage Control Surgery Over the World in Acute Diverticulitis (DACOSAD)

To analyze the possible benefit of damage control surgery by performing bowel resection, open abdomen, and delayed anastomosis in the treatment of Hinchey III or IV diverticulitis.

Hartmann procedure (HP) is still widely performed in the treatment of purulent or fecal generalized peritonitis as a consequence of a complicated acute large bowel diverticulitis (the so labeled III and IV grade of the Hinchey's classification). More than half of those patients do not undergo to stoma reversal because of its association with significant morbidity and mortality. To date, the use of resection with primary anastomosis (PA) should be preferred, as it is reported in the literature that it is more favorable than HP in terms of morbidity, mortality, and length of postoperative stay. However, PA is often reserved for younger patients with few co-morbidities and a lesser degree of peritoneal contamination while HP is performed in the elderly. Initially described for the treatment of major abdominal injuries, indications for Damage Control Surgery (DCS) have subsequently been extended to septic shock, abdominal compartment syndrome and impossibility to perform a primary closure. In the last decade, DCS has emerged as a valid alternative to HP and Resection-Anastomosis (RA) in patients presenting a severe sepsis caused by purulent or fecal peritonitis in acute diverticulitis. Although DCS is cited as an option in case of impaired hemodynamic status in face of perforated acute diverticulitis, there is still no consensus about such use of DCS. Previous study demonstrated that DCS reduce the Hartmann rate in patients otherwise scheduled for such procedure.

The aim of this study was to describe the potential rationale and outcome of the Damage Control Surgery in patients with purulent and fecal peritonitis.

Eligibility Criteria:
Inclusion Criteria:

* Patients \>18 year-old underwent surgery for Hinchey III and IV and submitted to resection, clip and drop, and open abdomen

Exclusion Criteria:

* Subjects \<18 year-old
Abriendo Caminos 2: Clearing the Path to Hispanic Health

Obesity is significantly higher in specific ethnic groups and, in particular, Hispanics. There is an urgent need to implement culturally-sensitive lifestyle interventions and educational programs to decrease the burden of obesity and obesity-related metabolic diseases in Hispanic populations. Accordingly, our overreaching goal is to tailor an existing and successful community-based program, Abriendo Caminos, to leverage effectiveness in promoting healthy nutrition and life-style behaviors among low income, low literacy Hispanic-heritage families. Our multi-function integrated project proposes to (a) adapt Abriendo Caminos for 6-18 year-old children from Mexican and Puerto Rican heritage in five different locations (California, Illinois, Iowa, Puerto Rico, and Texas) and (b) Train existing professionals (in Extension and community agencies) and future professionals (Hispanic university students) to meet the specific needs of this population. Our central hypothesis is that participation in a 6-week community-based program will prevent childhood obesity/maintain healthy weight by significantly increasing: (a) healthy dietary behavior patterns and basic knowledge of nutrition; (b) physical activity levels; and (c) the organization of collective/shared family mealtimes. The implementation of this culturally sensitive, workshop-based curriculum in different regions across the country will help to train the next generation of professionals in Extension and communities to deliver programs that meet the needs of Hispanic families. The integration of Hispanic college students in program implementation via an experiential learning course will further strengthen the program, as well as increase recruitment and retention of Hispanic students, increasing the capacity of Hispanic communities to meet their own needs in the future.


Eligibility Criteria:
Inclusion Criteria:

* a family member being 6-18 years of age
* at least 1 parent being of Hispanic-heritage from Mexican or Puerto Rican origin

Exclusion Criteria:

* no child in the age range of 6-18 years of age
* No parents being of Hispanic-heritage from Mexican or Puerto Rican origin
Effect of 0.1% Pilocarpine Mouthwash on Xerostomia

The aim of this study is to evaluate the effect of 0.1% pilocarpine mouthwash on subjective dryness, minor salivary flow rates and unstimulated whole salivary flow rate in xerostomic patients.


Eligibility Criteria:
Inclusion Criteria:

* xerostomia for 3 months or more, and
* adults aged 20 years and older.

Exclusion Criteria:

* acute asthma attack
* acute iritis
* narrow angle glaucoma
* pilocarpine allergy
* pregnancy
* lactating women, and
* person who was treating xerostomia with artificial saliva, pilocarpine, or etc.
CPR Quality in Via Ferrata Rescues

This study evaluates the effectiveness of CPR during via ferrata rescues, focusing on response quality and outcomes in challenging outdoor settings.

This study investigates the quality of Cardiopulmonary Resuscitation (CPR) provided during via ferrata rescues, where challenging terrain pose unique challenges to lifesaving efforts. Via ferratas are popular adventure routes that often require swift emergency responses in cases of cardiac events or accidents. Our comprehensive case report scrutinizes CPR performance in these high-risk settings, examining critical factors such as compressions quality, rescue team coordination and safety. By shedding light on the effectiveness of CPR in via ferrata scenarios, this research aims to improve safety protocols and enhance the chances of survival for adventurers facing cardiac emergencies in remote and demanding environments.

Eligibility Criteria:
Inclusion Criteria:

* professional provider of first aid (e. g. paramedic, fire fighter, physician)
* healthy provider (e. g. no active healthcare problem that can compromise the quality of CPR)

Exclusion Criteria:

* active health care problem (e. g. fever, cough, cold etc.)
* inability to provide safety on via ferrata
Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies

Bronchopulmonary Dysplasia (BPD) is the most frequent disease related to a premature birth, 15-50% of very low birth newborns (\<1500 gr.) will develop BPD. The prevalence of BPD is increasing due to the advances in neonatology, with a rise in the survival of smaller and more premature babies. The etiology of BPD is multifactorial, in which oxygen, maternal chorioamnionitis, insufficient pulmonary maturation etc. have an important role. These factors lead to a pathological development of the lung and pulmonary vessels, developing secondary Pulmonary Hypertension (PH). Nowadays there is no efficient treatment; this generates a important sanitary burden and a decrease in life quality. Multiple experimental models in mice have studied Mesenchymal Stem Cell (MSC) therapy as prevention of BPD, also recently some clinical trials have tried this therapy on premature newborns with promising results. Hypothesis: MSC therapy in patients at high risk of BPD prevents pulmonary lesions. Methods: The investigators have designed a clinical trial to evaluate the feasibility and security of MSC therapy in patients at high risk of developing BPD.


Eligibility Criteria:
Inclusion Criteria:

* Preterm newborns ≤ 28 weeks gestational age
* Birth Weight \<1250 gr.
* Still on of mechanical ventilation FiO2 \> 0,3 at day + 14

Exclusion Criteria:

* Other congenital pathology (pulmonary malformations, active pulmonary bleeding, renal malformations, CHD, malformative syndromes, chromosomopathies)
* Severe neurological lesion.
* HIV infection
* Cardiovascular instability due to any cause
* 72 hours after mayor surgery
* Necrotizing enterocolitis grades II or higher, according to Bell classification, at the time of inclusion.